Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
Status:
Active, not recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a single arm open-label design study looking at Nivolumab plus Ipilimumab in patients
with Advanced Neuroendocrine Tumors. Patients will be dosed Nivoluma 240mg IV over 60 minutes
every 2 weeks and Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks. Once cycle will include
3 doses of Nivolumab and 1 dose of Ipilimumab. The objective of this study is to evaluate the
objective response rate of combination nivolumab and ipilimumab in advanced,
well-differentiated neuroendocrine tumors. Durability of response, and PFS will also be
described.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins